menu
    • menu
    [{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Allergan"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inimmune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Inimmune","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inimmune"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-Fetoprotein","moa":"Alpha-fetoprotein receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Alpha Cancer Technologies"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"Bacterial DNA gyrase","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCAR Bio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Immunology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA\/CD3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KITE-363","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Merger","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Magenta Therapeutics \/ Dianthus Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Dianthus Therapeutics"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C CCX168","moa":"C5a1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LIFE-001","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase I","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LifeMine Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LifeMine Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Immunology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PF-07054894","moa":"C-C chemokine receptor type 6 (CCR6)","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Makana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"TNX-1500","moa":"||CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Makana Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Makana Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MaxCyte","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ TG Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ TG Therapeutics"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BMS-986515","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CB-010","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":2.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"CPTX2309","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Capstan Therapeutics","amount2":2.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.1000000000000001,"dosageForm":"Infusion","sponsorNew":"Capstan Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Capstan Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DR-0201","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dren Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"SAR448501","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Injection","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"SAR448501","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Injection","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CND261","moa":"CD20 | CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ALPN-101","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Gebro Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"CASI Pharmaceuticals \/ Gebro Pharma","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Gebro Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BMS-986325","moa":"CD40","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"CFB","graph1":"Immunology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"cGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"cGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CDX-0159","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Undisclosed"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Morgan Stanley"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"THB335","moa":"c-KIT receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Cowen"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"Desmoglein-3 (DSG3)","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"SL-325","moa":"DR3","graph1":"Immunology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ OrbiMed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Immunology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Novotech"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ National Institutes of Health"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"HARS","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Undisclosed"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Gummy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ADL-018","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BHV-1300","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BHV-1300","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20111117","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Cugene","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cugene \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ AbbVie Inc"},{"orgOrder":0,"company":"Cugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ Undisclosed"},{"orgOrder":0,"company":"Cugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PN-232","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2-beta-receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG592","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AMG592","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.69999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.69999999999999996,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NSHO-101","moa":"Integrin-alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensho Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Zura Bio"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AEVI-007","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efavaleukin Alfa","moa":"interleukins: interleukin-2 analogues and derivatives; Fc fusion protein","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efmarodocokin Alfa","moa":"interleukins; Fc fusion protein","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"BGB-45035","moa":"IRAK4","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Liquid Filled","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Briquilimab","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Jasper Therapeutics \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.54000000000000004,"dosageForm":"Undisclosed","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw Research \/ Eli Lilly"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LABP-104","moa":"LanC-like protein 2 (LANCL2)","graph1":"Immunology","graph2":"Phase I","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIB7734","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viela Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Immunology","graph2":"Phase I","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Simbec-Orion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Simbec-Orion","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Simbec-Orion"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bacainn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bacainn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adiso Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JNJ-67484703","moa":"PD-1","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"AbGenomics B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ AbGenomics B.V","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ AbGenomics B.V"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"AltruBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"P-selectin glycoprotein ligand 1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"Receptor-interacting protein 1 (RIPK1)","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0.95999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.95999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GDC-8264","moa":"RIPK1","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"GV101","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Concentra Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Concentra Biosciences"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OSSM-001","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Phase I","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ossium Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ossium Health \/ Undisclosed"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.1599999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT115301","moa":"T-cell effector","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Afimetoran","moa":"TLR4 receptor antagonists","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ ALS Association"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TNF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TNF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Biosciences \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF-alpha\/IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF-alpha\/IL-23 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Private Placement","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Immunology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Undisclosed"},{"orgOrder":0,"company":"Inimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Toll-like-4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-1334","moa":"Transforming growth factor beta 1 (TGFB1)","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Cerecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BGB-23339","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Neuron23","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NEU-111","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuron23 \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Surveyor Capital"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Viela Bio"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F LY3950321","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"AGENT-797","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MiNK Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMG732","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AprilBio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"APB-R3","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ AprilBio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ AprilBio"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Baylx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CDX-622","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"CND106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ US Department of Defense"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL730","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GIM-407","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Georgiamune \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GS-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GS-0272","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Holoclara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HC002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Holoclara","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holoclara \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Holoclara \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Himuka AM Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Himuka AM Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Himuka AM Pharma"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"IgGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JNJ-66525433","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-9","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inflammasome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LCAR-AIO T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Luminary Therapeutics","sponsor":"Nationwide Children","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"LMY-920","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Luminary Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luminary Therapeutics \/ Nationwide Children","highestDevelopmentStatusID":"6","companyTruncated":"Luminary Therapeutics \/ Nationwide Children"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LUCAR-DKS1 NK Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LUCAR-G79 T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MK-2225","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Penn Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Penn Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Penn Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Penn Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"P-CD19CD20-ALLO1 Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RO7303509","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SBT777101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SER-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Suono Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SUO-2002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Suono Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SYNCAR-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"Synthekine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNX-2110","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Premier Research Group"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thetis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Outer Lining Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZB001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ZB002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":2.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.25,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":2.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":2.25,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BMS-986454","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome ...

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 05, 2020

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shattuck Labs

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : OrbiMed

                            Deal Size : $103.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Shattuck Labs Announces Oversubscribed Private Placement upto $103 Million

                            Details : The net proceeds are expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease.

                            Product Name : SL-325

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 05, 2025

                            Lead Product(s) : SL-325

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : OrbiMed

                            Deal Size : $103.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adicet Bio

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Adicet Bio

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADI-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

                            Details : ADI-001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 03, 2025

                            Lead Product(s) : ADI-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Legend Biotech

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Legend Biotech

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LUCAR-DKS1 NK Cell

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of LUCAR-DKS1 in Subjects with Relapsed/Refractory Autoimmune Diseases

                            Details : LUCAR-DKS1 NK Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : LUCAR-DKS1 NK Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AgelessRx

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            AgelessRx

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Microdosed GLP-1 on Health, Quality of Life & Longevity

                            Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Inflammation.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 30, 2025

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allogene Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Allogene Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALLO-329

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ALLO-329 Allogeneic CAR-T Safety and Preliminary Efficacy In Autoimmune Disease

                            Details : ALLO-329 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 25, 2025

                            Lead Product(s) : ALLO-329

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Legend Biotech

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Legend Biotech

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LUCAR-G79 T Cell

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of LUCAR-G79 in Subjects with Relapsed/Refractory Autoimmune Diseases

                            Details : LUCAR-G79 T Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : LUCAR-G79 T Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MiNK Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            MiNK Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGENT-797

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            MiNK Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy

                            Details : The grant will support development of MiNK’s allo-iNKT cell therapy, AGENT-797, for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 02, 2025

                            Lead Product(s) : AGENT-797

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kashiv BioSciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Kashiv BioSciences

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADL-018

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Open Label ,Randomized, Balanced, Two-treatment, Single Period, Parallel, Comparative Pharmacokinetic Study ...

                            Details : ADL-018 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Urticaria.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : ADL-018

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Palisade Bio

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Palisade Bio

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PALI-2108

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palisade Completes Dosing in Phase 1a PALI-2108 Clinical Study

                            Details : PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : PALI-2108

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth